SLC7A11 and malignant colon neoplasm: Furthermore, in LPCAT2 knockout mice (LPCAT2−/−) colon cancer model, we found that LPCAT2−/− mice exhibited more severe lesions, while PRMT1 or SLC7A11 inhibitors delayed the progression.